Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.32 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17792008 | 0.93 | CYP1A2 (0.37) | CYP1A2ERBB2FYNMAOAACHE | |
| SCHEMBL17791954 | 0.93 | CYP1A2 (0.37) | CYP1A2ERBB2FYNMAOAACHE | |
| SCHEMBL17791970 | 0.88 | RAB9A (0.33) | CYP1A2ERBB2FYNMAOAACHE | |
| SCHEMBL17792016 | 0.88 | RAB9A (0.33) | CYP1A2ERBB2FYNMAOAACHE | |
| SCHEMBL17791965 | 0.87 | CYP1A2 (0.36) | CYP1A2ERBB2FYNMAOAACHE | |
| SCHEMBL17792037 | 0.86 | CYP19A1 (0.33) | CYP19A1CYP1A2ERBB2FYNMAOA | |
| SCHEMBL17792038 | 0.86 | ALDH1A1 (0.43) | CYP1A2ERBB2FYNMAOAACHE | |
| SCHEMBL17791986 | 0.86 | — | — | |
| SCHEMBL12575566 | 0.85 | CYP1A2 (0.33) | CYP19A1CYP1A2ERBB2FYNMAOA | |
| SCHEMBL17791960 | 0.84 | ERBB2 (0.31) | CYP1A2ERBB2FYNMAOAACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9793491-B2 | Compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-10-17 | — | — | US | disclosed |
| US-9793491-B2 | Compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-10-17 | — | — | US | disclosed |
| US-20160155952-A1 | COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-06-02 | — | — | US | disclosed |
| US-20160155952-A1 | COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160155952-A1 | COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | TMEM109, USE1, TRPC1 | CYP19A1 266/4885CYP1A2 633/4885ERBB2 4581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.